RY 171.23 -1.0746% SHOP 170.14 2.1432% TD 81.85 -0.7879% ENB 62.92 0.5594% BN 84.78 -1.8636% TRI 244.07 -0.9215% CNQ 44.44 1.6236% CP 111.16 2.0753% CNR 147.09 2.2595% BMO 140.35 -1.2315% BNS 72.0 -0.0971% CSU 4795.7002 -0.5041% CM 88.52 1.351% MFC 42.53 -0.3047% ATD 76.2 1.3163% NGT 62.42 -0.5893% TRP 66.63 1.0005% SU 55.02 0.5299% WCN 269.74 -1.0927% L 182.96 1.4416%
Last update at 2025-02-04T18:52:00Z
GEHC Stock May Gain on FDA's Nod for the Updated Voluson Expert Series
Mon 03 Feb 25, 04:38 PMHere's Why ResMed (RMD) is a Strong Momentum Stock
Mon 03 Feb 25, 02:50 PMResMed Insiders Sold US$17m Of Shares Suggesting Hesitancy
Sun 02 Feb 25, 11:00 AMResMed (NYSE:RMD) Posts Better-Than-Expected Sales In Q4 But Stock Drops
Fri 31 Jan 25, 08:32 PMResMed Inc. (RMD) Hits Fresh High: Is There Still Room to Run?
Fri 31 Jan 25, 02:15 PMResMed Q2 Earnings and Revenues Beat, Stock Up in Pre-Market
Fri 31 Jan 25, 02:14 PMANGO Stock Looks Promising on New Ischemia Study for Auryon System
Fri 31 Jan 25, 02:07 PMQ2 2025 Resmed Inc Earnings Call
Fri 31 Jan 25, 01:55 PMResMed Inc (RMD) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Fri 31 Jan 25, 07:40 AMCompared to Estimates, ResMed (RMD) Q2 Earnings: A Look at Key Metrics
Thu 30 Jan 25, 11:30 PM| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | 1101.66M | 960.48M | 883.66M | 733.09M | 518.85M |
| Minority interest | - | - | - | - | - |
| Net income | 897.56M | 779.44M | 474.50M | 621.67M | 404.59M |
| Selling general administrative | 874.00M | 739.37M | 670.39M | 676.69M | 645.01M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 2355.66M | 2024.31M | 1839.10M | 1717.79M | 1536.59M |
| Reconciled depreciation | 197.56M | 193.84M | 191.52M | 181.37M | 150.79M |
| Ebit | 1141.97M | 1000.29M | 903.68M | 809.66M | 579.26M |
| Ebitda | 1339.54M | 1194.13M | 1112.54M | 989.83M | 843.50M |
| Depreciation and amortization | 197.56M | 193.84M | 208.86M | 180.17M | 264.24M |
| Non operating income net other | - | - | - | -36.19400M | -24.26000M |
| Operating income | 1131.87M | 1000.29M | 903.68M | 809.66M | 579.26M |
| Other operating expenses | 3071.00M | 2577.84M | 2284.47M | 2147.95M | 1970.59M |
| Interest expense | 47.38M | 22.31M | 23.99M | 40.38M | 36.16M |
| Tax provision | 204.11M | 181.05M | 409.16M | 111.41M | 114.25M |
| Interest income | 44.72M | 43.00M | 34.83M | 63.08M | 2.30M |
| Net interest income | -47.37900M | -22.31200M | -23.62700M | -39.35600M | -33.85700M |
| Extraordinary items | - | - | - | - | -6.65400M |
| Non recurring | - | - | - | -0.60000M | 56.72M |
| Other items | - | - | - | - | - |
| Income tax expense | 204.11M | 181.05M | 409.16M | 111.41M | 114.25M |
| Total revenue | 4222.99M | 3578.13M | 3196.82M | 2957.01M | 2606.57M |
| Total operating expenses | 1203.66M | 1024.03M | 926.75M | 908.73M | 900.60M |
| Cost of revenue | 1867.33M | 1553.82M | 1357.72M | 1239.23M | 1069.99M |
| Total other income expense net | -2.95400M | -39.80300M | -20.01600M | -76.57100M | -60.41600M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 897.56M | 779.44M | 474.50M | 621.67M | 404.59M |
| Net income applicable to common shares | 897.56M | 779.44M | 780.39M | 621.67M | 404.59M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Total assets | 6751.71M | 5095.85M | 4728.12M | 4587.38M | 4107.68M |
| Intangible assets | 552.34M | 345.94M | 392.58M | 448.17M | 521.95M |
| Earning assets | - | - | - | - | - |
| Other current assets | 437.02M | 337.91M | 208.15M | 168.75M | 120.11M |
| Total liab | 2621.80M | 1735.10M | 1842.45M | 2090.35M | 2035.49M |
| Total stockholder equity | 4129.90M | 3360.75M | 2885.68M | 2497.03M | 2072.19M |
| Deferred long term liab | - | - | - | 13.01M | 11.38M |
| Other current liab | 437.88M | 389.62M | 628.56M | 335.11M | 339.61M |
| Common stock | 0.59M | 0.59M | 0.58M | 0.58M | 0.57M |
| Capital stock | 0.59M | 0.59M | 0.58M | 0.58M | 0.57M |
| Retained earnings | 4253.02M | 3613.74M | 3079.64M | 2832.99M | 2436.41M |
| Other liab | 315.19M | 160.03M | 172.55M | 221.57M | 220.64M |
| Good will | 2770.30M | 1936.44M | 1927.90M | 1890.32M | 1856.45M |
| Other assets | 261.31M | 202.29M | 240.82M | 145.60M | 144.35M |
| Cash | 227.89M | 273.71M | 295.28M | 463.16M | 147.13M |
| Cash and equivalents | - | 273.71M | 295.28M | 463.16M | 147.13M |
| Total current liabilities | 758.53M | 689.30M | 911.77M | 602.76M | 555.99M |
| Current deferred revenue | 138.07M | 108.67M | 109.61M | 98.62M | 88.67M |
| Net debt | 1352.02M | 643.84M | 498.44M | 836.11M | 1123.72M |
| Short term debt | 31.82M | 31.77M | 35.59M | 33.25M | 11.99M |
| Short long term debt | 9.90M | 9.92M | 12.00M | 11.99M | 11.99M |
| Short long term debt total | 1579.91M | 917.55M | 793.72M | 1299.26M | 1270.85M |
| Other stockholder equity | 148.83M | 59.18M | -1.05700M | -52.56200M | -111.78300M |
| Property plant equipment | 665.81M | 630.50M | 592.07M | 535.68M | 387.46M |
| Total current assets | 2367.83M | 1931.48M | 1574.76M | 1523.46M | 1145.37M |
| Long term investments | - | - | - | - | 52.10M |
| Net tangible assets | 807.26M | 1078.37M | 565.20M | 158.53M | -306.20600M |
| Short term investments | - | - | - | - | - |
| Net receivables | 704.91M | 575.95M | 614.29M | 474.64M | 528.48M |
| Long term debt | 1431.23M | 765.33M | 643.35M | 1164.13M | 1258.86M |
| Inventory | 998.01M | 743.91M | 457.03M | 416.92M | 349.64M |
| Accounts payable | 150.76M | 159.25M | 138.01M | 135.79M | 115.72M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -272.52800M | -312.74700M | -193.48700M | -283.98200M | -253.00900M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.58M | 0.58M | 0.57M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | 2832.99M | 2436.41M |
| Treasury stock | - | - | -1623.25600M | -1623.25600M | -1623.25600M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 395.43M | 251.49M | 240.82M | 189.74M | 196.46M |
| Deferred long term asset charges | - | - | - | - | 45.48M |
| Non current assets total | 4383.88M | 3164.38M | 3153.37M | 3063.92M | 2962.32M |
| Capital lease obligations | 138.77M | 142.31M | 138.36M | 123.14M | - |
| Long term debt total | - | 765.33M | 643.35M | 1164.13M | 1258.86M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -1159.84500M | -13.92200M | -158.46200M | -46.01300M | -46.98100M |
| Change to liabilities | 31.34M | -247.63200M | 210.71M | -23.42400M | -27.27800M |
| Total cashflows from investing activities | -1159.84500M | -229.91800M | -158.46200M | -179.86100M | -1075.70600M |
| Net borrowings | 665.00M | 122.00M | -522.00000M | -94.01200M | 807.49M |
| Total cash from financing activities | 422.87M | -128.36300M | -764.63200M | -317.28600M | 580.64M |
| Change to operating activities | -138.12500M | -168.10900M | -58.15400M | -58.99900M | -47.57500M |
| Net income | 897.56M | 779.44M | 474.50M | 621.67M | 404.59M |
| Change in cash | -45.81900M | -21.56800M | -167.87800M | 316.03M | -41.57300M |
| Begin period cash flow | 273.71M | 295.28M | 463.16M | 147.13M | 188.70M |
| End period cash flow | 227.89M | 273.71M | 295.28M | 463.16M | 147.13M |
| Total cash from operating activities | 693.30M | 351.15M | 736.72M | 802.25M | 459.05M |
| Issuance of capital stock | 49.14M | 47.38M | 37.79M | 48.18M | 36.73M |
| Depreciation | 197.56M | 193.84M | 191.52M | 181.37M | 150.79M |
| Other cashflows from investing activities | -1025.84500M | -17.17600M | -41.63600M | -38.51800M | -960.01500M |
| Dividends paid | 258.28M | 245.34M | 226.71M | 225.09M | 211.71M |
| Change to inventory | -248.83300M | -311.68100M | -21.95400M | -69.88100M | -84.18800M |
| Change to account receivables | -106.51100M | 19.35M | -129.19500M | 54.38M | -18.01300M |
| Sale purchase of stock | 1070.00M | 47.38M | 90.00M | 1190.00M | -22.84400M |
| Other cashflows from financing activities | -32.99200M | 235.59M | -53.70900M | -46.36300M | 1490.22M |
| Change to netincome | 60.31M | 85.94M | 69.29M | 82.61M | 80.72M |
| Capital expenditures | 134.00M | 156.04M | 116.83M | 105.94M | 77.34M |
| Change receivables | - | - | - | 54.38M | -18.01300M |
| Cash flows other operating | - | - | - | -17.95700M | -47.57500M |
| Exchange rate changes | - | - | - | 10.92M | -5.56100M |
| Cash and cash equivalents changes | - | - | - | 316.03M | -41.57300M |
| Change in working capital | -462.12700M | -708.07600M | 1.41M | -97.92100M | -177.05400M |
| Stock based compensation | 71.14M | 65.26M | 63.93M | 57.56M | 52.07M |
| Other non cash items | -11.05000M | 20.69M | 8.67M | -0.00700M | -0.28600M |
| Free cash flow | 559.30M | 195.11M | 619.89M | 696.32M | 381.71M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| RMD ResMed Inc |
-0.155 0.06% | 240.40 | 27.87 | 24.81 | 5.85 | 6.02 | 6.14 | 19.59 |
| ISRG Intuitive Surgical Inc |
-0.245 0.04% | 578.30 | 73.05 | 61.73 | 19.15 | 10.25 | 18.41 | 59.92 |
| ESLOY Essilor International SA |
3.52 2.59% | 139.22 | 35.39 | 24.81 | 3.63 | 2.20 | 4.00 | 16.25 |
| ESLOF EssilorLuxottica Société anonyme |
- -% | 269.88 | 35.71 | 25.13 | 3.62 | 2.23 | 4.00 | 16.25 |
| BDX Becton Dickinson and Company |
-4.27 1.72% | 243.34 | 37.72 | 15.92 | 3.25 | 2.49 | 4.08 | 17.10 |
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.
9001 Spectrum Center Boulevard, San Diego, CA, United States, 92123
| Name | Title | Year Born |
|---|---|---|
| Dr. Peter C. Farrell A.M., AM, B.E., BE (Hons), Ph.D., ScD | Founder & Non-Exec. Chairman | 1942 |
| Mr. Michael J. Farrell BE, MBA, SM | CEO & Director | 1972 |
| Mr. Robert A. Douglas | Pres & COO | 1960 |
| Mr. Brett A. Sandercock | Chief Financial Officer | 1967 |
| Mr. David B. Pendarvis | Chief Admin. Officer, Global Gen. Counsel & Corp. Sec. | 1959 |
| Mr. Kaushik Ghoshal | Pres of SaaS Bus. | 1968 |
| Ms. Urvashi Tyagi | Chief Technology Officer | NA |
| Ms. Constance C. Bienfait | Director of Investor Relations | NA |
| Ms. Amy Wakeham | VP of Investor Relations & Corp. Communications | NA |
| Ms. Vered Keisar | Chief People Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...